Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Year: 2017
Type: article
Institutions: Boston Medical Center, Boston Children's Hospital, University of California, San Francisco, Children's Hospital of Philadelphia, University of North Carolina at Chapel Hill, Yale University, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, The University of Texas Southwestern Medical Center, New York University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
Awards: Biostatistics Data Management Center for ACRIN, Integrated Biomarkers to Characterize Breast Cancer Risk, G1209692471, G1406545193, G1814228702, American College of Radiology Imaging Network, G3298934708, G3406370123, G3581085865, G3583859132, G3690325657, G3744195242, G4040562365, G4257885129, Biostatistics Data Management Center for ACRIN, G5643875679, G595549979, Cancer and Leukemia Group B, NCTN Lead Academic Participating Sites Application, G7454439745, G7473554490, G847186934, Alliance for Clinical Trials in Oncology Operations Center, G973482110
OpenAlex ID: W2620769019